Prediction of ineffectiveness of biological drugs using machine learning and explainable AI methods: data from the Austrian Biological Registry BioReg
Abstract Objectives Machine learning models can support an individualized approach in the choice of bDMARDs. We developed prediction models for 5 different bDMARDs using machine learning methods based on patient data derived from the Austrian Biologics Registry (BioReg). Methods Data from 1397 patie...
Main Authors: | Dubravka Ukalovic, Burkhard F. Leeb, Bernhard Rintelen, Gabriela Eichbauer-Sturm, Peter Spellitz, Rudolf Puchner, Manfred Herold, Miriam Stetter, Vera Ferincz, Johannes Resch-Passini, Jochen Zwerina, Marcus Zimmermann-Rittereiser, Ruth Fritsch-Stork |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2024-02-01
|
Series: | Arthritis Research & Therapy |
Subjects: | |
Online Access: | https://doi.org/10.1186/s13075-024-03277-x |
Similar Items
-
Drug survival of second biological DMARD therapy in patients with rheumatoid arthritis: a retrospective non-interventional cohort analysis
by: Thomas Wilke, et al.
Published: (2017-08-01) -
Risk of cancer for patients with rheumatoid arthritis versus general population: a national claims database cohort studyResearch in context
by: Maxime Beydon, et al.
Published: (2023-12-01) -
Biological treatment and exercise as an alternative to typical rheumatoid arthritis therapy: pathophysiology and effects
by: Artur Aghadi, et al.
Published: (2023-02-01) -
Impact of multimorbidity on the first ts/bDMARD effectiveness and retention rate after two years of follow-up in patients with rheumatoid arthritis from the BIOBADASER registry
by: Jerusalem Calvo-Gutiérrez, et al.
Published: (2024-02-01) -
The RA-BE-REAL Multinational, Prospective, Observational Study in Patients with Rheumatoid Arthritis Receiving Baricitinib, Targeted Synthetic, or Biologic Disease-Modifying Therapies: a 6-Month Interim Analysis
by: Rieke Alten, et al.
Published: (2022-10-01)